1CHOW WH,DEVESA SS,WARREN JL,et al.Rising incidence of renal cell cancer in the United States[J].JAMA,1999,281:1628-1631.
2ZISMAN A,PANTUCK AJ,WIEDER J,et al.Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma[J].J Clin Oncol,2002,20:4559-4566.
3MOTZER RJ,BACIK J,SCHWARTZ LH,et al.Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma[J].J Clin Oncol,2004,22:454-463.
5KONDO K,YAO M,YOSHIDA M,et al.Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma:relationship to clinicopathological parameters[J].Genes Chromosomes Cancer,2002,34:58-68.
6IGARASHI H,ESUMI M,ISHIDA H,et al.Endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma[J].Cancer,2002,95:47-53.
8SUN L.LIANG C,SHIRAZIAN S,et al.Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl] -2,4-dimethyl-1Hpyrrole-3-carboxylic acid(2-diethylaminoethyl)amide,a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase[J].J Med Chem,2003,46:1116-1119.
9O'FARELL AM,ABRAMS TJ,YUEN HA,et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo[J].Blood,2003,101:3597-3605.
10MENDEL DB,LAIRD AD,XIN X,et al.,In vivo antitumor activity of SU11248,a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:determination of a pharmacokinetic/ pharmacodynamic relationship[J].Clin Cancer Res,2003,9:327-337.
二级参考文献10
1Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356: 125-134.
2Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
3Stadler WM, Halabi S, Rini B, et al. Cancer and Leukemia Group B. A phase Ⅱ study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer, 2006, 107: 1273-1279.
4Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol, 2007, 37: 755-762.
5Ryan CW, Bukowski RM, Figlin RA, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in firstline patients (pts). J Clin Oncol, 2007, 25: 5096.
6Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356 : 125-134.
7Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24: 2505-2512.
